Unicycive Therapeutics, Inc.
UNCY
$4.20
-$0.05-1.18%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | 0.00 | 0.00 |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | 0.00 | 0.00 |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | 0.00 | 0.00 |
SG&A Expenses | 18.21M | 15.53M | 12.10M | 10.21M | 9.57M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 30.46M | 30.90M | 32.12M | 29.17M | 28.86M |
Operating Income | -30.46M | -30.90M | -32.12M | -29.17M | -28.86M |
Income Before Tax | -31.50M | -15.20M | -36.73M | -23.00M | -23.24M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -31.50 | -15.20 | -36.73 | -23.00 | -23.24 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -31.50M | -15.20M | -36.73M | -23.00M | -23.24M |
EBIT | -30.46M | -30.90M | -32.12M | -29.17M | -28.86M |
EBITDA | -30.44M | -30.88M | -32.10M | -29.15M | -28.84M |
EPS Basic | -2.98 | 1.48 | -6.34 | -6.54 | -7.43 |
Normalized Basic EPS | -1.86 | 0.09 | -3.69 | -3.82 | -4.36 |
EPS Diluted | -3.52 | -4.46 | -11.73 | -11.93 | -12.82 |
Normalized Diluted EPS | -1.86 | -0.88 | -4.66 | -4.79 | -5.33 |
Average Basic Shares Outstanding | 43.45M | 34.94M | 26.75M | 19.66M | 14.03M |
Average Diluted Shares Outstanding | 44.15M | 41.26M | 32.36M | 25.27M | 19.64M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | 0.00% | -7.21% | -2.98% | -4.76% | -4.71% |